https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg
0
0
Editor
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg
Editor2016-08-01 09:00:002022-08-17 15:16:25Autifony Therapeutics successfully completes Phase I study of AUT00206, a first-in-class Kv3 modulator for schizophrenia
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg
0
0
Editor
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg
Editor2016-07-06 09:00:502022-08-17 15:16:31Autifony Therapeutics initiates QuicK+fire, a pilot study of AUT00063 in adult cochlear implant users
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg
0
0
Editor
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg
Editor2016-04-28 09:00:102022-08-17 15:16:38Update from Autifony Therapeutics’ QUIET-1 tinnitus clinical trial
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg
0
0
Editor
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg
Editor2015-11-24 09:00:102022-08-17 15:16:46Autifony Therapeutics initiates Phase I study of AUT00206, a novel treatment approach for schizophrenia
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg
0
0
Editor
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg
Editor2015-10-13 09:00:062022-08-17 15:16:53Update from Autifony Therapeutics’ QUIET-1 clinical trial
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg
0
0
Editor
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg
Editor2015-09-03 09:00:282022-08-17 15:16:58Dr John Hutchison joins Autifony Therapeutics as Chief Medical Officer
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg
0
0
Editor
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg
Editor2015-07-10 09:00:382022-08-17 15:17:05Autifony Therapeutics extends Series A with £8 million for hearing disorders and schizophrenia clinical trials
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg
0
0
Editor
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg
Editor2015-04-27 09:00:422022-08-17 15:17:11Autifony Therapeutics recruits first patient into Phase IIa trial for first-in-class drug to treat Age Related Hearing Loss. Study follows acceptance of Autifony’s first IND by the FDA
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg
0
0
Editor
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg
Editor2015-04-16 09:00:362022-08-17 15:17:19Autifony Therapeutics announces £3.3 million collaboration to progress first-in-class drug for schizophrenia into clinical trials
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg
0
0
Editor
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg
Editor2014-11-20 09:00:092022-08-17 15:17:26Autifony Therapeutics announces initiation of Phase IIa study for first-in-class drug to treat tinnitus
Scroll to top